Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 30;58(S1):S11-S12.
doi: 10.5045/br.2023.2023015. Epub 2023 Feb 27.

Practical issues in CAR T-cell therapy

Ja Min Byun  1
Affiliations
Review

Practical issues in CAR T-cell therapy

Ja Min Byun. Blood Res. .

Abstract

Chimeric antigen receptor (CAR) T-cell therapy presents a revolutionary advancement in personalized cancer treatment. During the production process, the patient's own T-cells are genetically engineered to express a synthetic receptor that binds to a tumor antigen. CAR T-cells are then expanded for clinical use and infused back into the patient's body to attack cancer cells. Although CAR T-cell therapy is considered a major breakthrough in cancer immunotherapy, it is not without limitations. In this review, we discuss the barriers to effective CAR T-cell therapy in Korea.

Keywords: Barrier; CAR T-cell therapy; Korea; Patient access.

PubMed Disclaimer

Conflict of interest statement

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

References

    1. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69. doi: 10.1038/s41408-021-00459-7.40c1ba0f2ef74dd8953be161f136eb35 - DOI - PMC - PubMed
    1. Geethakumari PR, Ramasamy DP, Dholaria B, Berdeja J, Kansagra A. Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments. Curr Hematol Malig Rep. 2021;16:345–56. doi: 10.1007/s11899-021-00635-3. - DOI - PMC - PubMed
    1. Yakoub-Agha I. Clinical units to set up chimeric antigen receptor T-cell therapy (CAR T-cells): based on the recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) Curr Res Transl Med. 2018;66:57–8. doi: 10.1016/j.retram.2018.04.001. - DOI - PubMed
    1. The Korean Ministry of Food and Drug Safety, author. Act on the safety of and support for advanced regenerative medicine and advanced biological products. Korea Legislation Research Institute; Sejong, Korea: 2020. [Accessed January 7, 2023]. at https://elaw.klri.re.kr/kor_service/lawTotalSearchList.do?pCode=37&type=... .
    1. Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA Netw Open. 2020;3:e202072. doi: 10.1001/jamanetworkopen.2020.2072. - DOI - PMC - PubMed